BD Oncomark™ Anti-Human CD79b FITC/Lambda PE/CD19 PerCP-Cy™5.5
Description
The CD79b antibody, clone SN8 (3A2-2E7-1F5), is generated from the fusion of NS-1 myeloma cells with spleen cells from BALB/c mice immunized with an antigen prepared from the membrane of B-prolymphocytic leukemia (B-PLL) cells. The Anti-Lambda antibody, clone 1-155-2, is derived from hybridization of P3-X63- Ag8.653 mouse myeloma cells with cells from BALB C/J mice immunized with human IgA1-λ myeloma protein. The CD19 antibody, clone SJ25C1, is derived from the hybridization of Sp2/0 mouse cells with spleen cells from BALB/c mice immunized with NALM1 + NALM16 cells. The CD79b antibody reacts with the CD79b protein and the epitope lies on the extra domain of the peptide. CD79b is helpful in delineating signal transduction pathway activated via antibody receptors during different stages of B-cell differentiation. The Anti-Lambda antibody is specific for lambda light chains of human immunoglobulins. The CD19 antibody recognizes a 90-kilodalton (kDa) antigen that is present on human B lymphocytes.
Preparation And Storage
Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.
| Description | Clone | Isotype | EntrezGene ID |
|---|---|---|---|
| N/A | N/A | | IgG1, λ,IgG1, κ,IgG1, κ | N/A |
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Although not required, these products are manufactured in accordance with Good Manufacturing Practices.